Nuvalent

61 articles about Nuvalent

• Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results

  11/14/2023

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline progress and reported third quarter 2023 financial results.

• Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology Day

  11/1/2023

  Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the BMO Virtual BioPharma Spotlight Series: Oncology Day on Wednesday, November 8, 2023, at 1:00 p.m. ET.

• Nuvalent Announces Pricing of Public Offering of Common Stock - October 17, 2023

  10/17/2023

  Nuvalent, Inc. announced the pricing of its previously announced underwritten public offering of 5,357,143 shares of Class A common stock at a price to the public of $56.00 per share.

• Nuvalent Announces Public Offering of Common Stock - October 16, 2023

  10/16/2023

  Nuvalent, Inc. announced that it has commenced an underwritten public offering of $300.0 million of its shares of Class A common stock.

• Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

  10/13/2023

  Nuvalent, Inc. announced updated preliminary data from the Phase 1 dose-escalation portion of its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with advanced ALK-positive non-small cell lung cancer and other solid tumors.

• Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety Profile

  10/4/2023

  Nuvalent, Inc. (Nasdaq: NUVL) today announced preliminary data from the Phase 1 dose-escalation portion of its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 for patients with advanced ALK-positive non-small cell lung cancer (NSCLC) and other solid tumors as reported in an abstract accepted for presentation at the 35th AACR-NCI-EORTC (ANE) Symposium in Boston, Massachusetts.

• Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium

  9/18/2023

  Nuvalent, Inc. announced it will present preliminary dose-escalation data from its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 at the 35th AACR-NCI-EORTC Symposium taking place October 11-15, 2023, in Boston, Massachusetts.

• Nuvalent Initiates the Phase 2 Portion of ARROS-1 Clinical Trial for Patients with ROS1-Positive NSCLC and other Solid Tumors

  9/5/2023

  Nuvalent, Inc. announced the initiation of the Phase 2 portion of ARROS-1, its Phase 1/2 clinical trial of NVL-520 for patients with ROS1-positive non-small cell lung cancer and other solid tumors, following alignment with the US Food and Drug Administration on a recommended Phase 2 dose of 100 mg daily.

• Nuvalent to Participate in Upcoming September 2023 Investor Conferences

  8/31/2023

  Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in fireside chats during the following September investor conferences:

• Nuvalent Highlights Pipeline Progress and Reports Second Quarter 2023 Financial Results

  8/10/2023

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline progress and reported second quarter 2023 financial results.

• Nuvalent to Participate in Upcoming August 2023 Investor Conferences

  8/1/2023

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in the following August investor conferences:

• Nuvalent to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

  5/24/2023

  Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the TD Cowen 4th Annual Oncology Innovation Summit on Wednesday, May 31, 2023, at 10:30 a.m. ET.

• Nuvalent Announces Anticipated Timing of Preliminary Phase 1 Dose-Escalation Data for NVL-655 and Reports First Quarter 2023 Financial Results

  5/11/2023

  Nuvalent, Inc. announced plans to share preliminary data from the dose-escalation portion of its ongoing ALKOVE-1 Phase 1/2 clinical trial for NVL-655, a novel ALK-selective inhibitor, in the second half of 2023, and reported first quarter 2023 financial results.

• Nuvalent to Participate in the Stifel 2023 Virtual Targeted Oncology Days

  4/19/2023

  Nuvalent, Inc. announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Stifel 2023 Virtual Targeted Oncology Days on Wednesday, April 26, 2023, at 1:30 p.m. ET.

• Nuvalent Presents New Preclinical Data Supporting Intracranial Activity of NVL-655 at AACR Annual Meeting 2023

  4/18/2023

  Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the presentation of new preclinical data supporting the intracranial activity NVL-655.

• Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)

  3/23/2023

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.

• Nuvalent Highlights Pipeline and Business Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

  3/16/2023

  Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline and business progress and fourth quarter and full year 2022 financial results.

• Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023

  3/14/2023

  Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming preclinical data poster presentation supporting the ongoing clinical development of its ALK-selective inhibitor, NVL-655.

• Nuvalent to Participate in the 43rd Annual Cowen Healthcare Conference

  3/1/2023

  Nuvalent, Inc. today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom , Chief Financial Officer, will participate in a fireside chat during the 43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023, at 9:10 a.m. ET in Boston. 

• Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/4/2023

  Nuvalent, Inc. today announced that James Porter, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023.